Andere Sprachen Omega Therapeutics, Inc.

Aktien

A3CWDR

US68217N1054

OMGA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 01.07.2024			% 5 Tage	% 1. Jan.
2,25 ^USD	+8,70 %		-7,02 %	-25,25 %

24.06.	Omega Therapeutics, Inc. ernennt Richard N. Kender zum Mitglied des Verwaltungsrats	CI
18.06.	OMEGA THERAPEUTICS, INC. : Raymond James bleibt bei seiner Kaufempfehlung	ZM

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors	24.06.
Omega Therapeutics, Inc. Appoints Richard N. Kender to Board of Directors	24.06.
Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer	13.06.
Omega Therapeutics, Inc. Announces Termination of Yan Moore as Chief Medical Officer	30.05.
Omega Therapeutics To Participate In Two Upcoming Investor Conferences	30.05.
Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer	29.05.
Omega Therapeutics, Inc. Appoints Kaan Certel, Ph.D., as Chief Business Officer	29.05.
Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers	08.05.
Omega Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	06.05.
Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress	06.05.
Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting	23.04.
Omega Therapeutics CFO Joshua Reed to Depart	16.04.
Omega Therapeutics, Inc. Announces Executive Changes, Effective as of May 31, 2024	16.04.
Omega Therapeutics, Inc. Designates Barbara Chan as Principal Accounting Officer, Effective as of May 31, 2024	16.04.
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	09.04.
Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control	09.04.
Omega Therapeutics, Inc. Presents New Preclinical Data At AACR 2024 Supporting the Potential of Precision Epigenomic Control	09.04.
Omega Therapeutics Cuts Headcount by 35%, Narrows Q4 Loss	28.03.
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update	28.03.
Omega Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Omega Therapeutics, Inc.

Aktien

A3CWDR

US68217N1054

OMGA

Andere Sprachen

Filter